In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

V. Mey, E. Giovannetti, F. De Braud, S. Nannizzi, G. Curigliano, F. Verweij, O. De Cobelli, S. Pece, M. Del Tacca, R. Danesi

Research output: Contribution to journalArticle

Abstract

The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples. The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Bladder tumour specimens showed an heterogeneous gene expression pattern and patients with higher levels of dCK and hENT1 had better response. Moreover, human nucleoside concentrative transporter-1 was detectable only in 3/12 patients, two of whom presented a complete response to gemcitabine. These data provide evidence that the chemotherapeutic activity of the combination of gemcitabine and pemetrexed is synergistic against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.

Original languageEnglish
Pages (from-to)289-297
Number of pages9
JournalBritish Journal of Cancer
Volume95
Issue number3
DOIs
Publication statusPublished - Aug 7 2006

Fingerprint

gemcitabine
Pemetrexed
Pharmacogenetics
Urinary Bladder Neoplasms
Deoxycytidine Kinase
Gene Expression
Nucleoside Transport Proteins
In Vitro Techniques
S Phase
Phosphorylation

Keywords

  • Antifolates
  • Bladder cancer
  • Drug combination
  • Gemcitabine
  • Inducible gene expression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. / Mey, V.; Giovannetti, E.; De Braud, F.; Nannizzi, S.; Curigliano, G.; Verweij, F.; De Cobelli, O.; Pece, S.; Del Tacca, M.; Danesi, R.

In: British Journal of Cancer, Vol. 95, No. 3, 07.08.2006, p. 289-297.

Research output: Contribution to journalArticle

@article{d898682af77b41169d9cb0872777ddef,
title = "In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients",
abstract = "The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples. The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Bladder tumour specimens showed an heterogeneous gene expression pattern and patients with higher levels of dCK and hENT1 had better response. Moreover, human nucleoside concentrative transporter-1 was detectable only in 3/12 patients, two of whom presented a complete response to gemcitabine. These data provide evidence that the chemotherapeutic activity of the combination of gemcitabine and pemetrexed is synergistic against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.",
keywords = "Antifolates, Bladder cancer, Drug combination, Gemcitabine, Inducible gene expression",
author = "V. Mey and E. Giovannetti and {De Braud}, F. and S. Nannizzi and G. Curigliano and F. Verweij and {De Cobelli}, O. and S. Pece and {Del Tacca}, M. and R. Danesi",
year = "2006",
month = "8",
day = "7",
doi = "10.1038/sj.bjc.6603242",
language = "English",
volume = "95",
pages = "289--297",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients

AU - Mey, V.

AU - Giovannetti, E.

AU - De Braud, F.

AU - Nannizzi, S.

AU - Curigliano, G.

AU - Verweij, F.

AU - De Cobelli, O.

AU - Pece, S.

AU - Del Tacca, M.

AU - Danesi, R.

PY - 2006/8/7

Y1 - 2006/8/7

N2 - The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples. The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Bladder tumour specimens showed an heterogeneous gene expression pattern and patients with higher levels of dCK and hENT1 had better response. Moreover, human nucleoside concentrative transporter-1 was detectable only in 3/12 patients, two of whom presented a complete response to gemcitabine. These data provide evidence that the chemotherapeutic activity of the combination of gemcitabine and pemetrexed is synergistic against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.

AB - The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples. The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Bladder tumour specimens showed an heterogeneous gene expression pattern and patients with higher levels of dCK and hENT1 had better response. Moreover, human nucleoside concentrative transporter-1 was detectable only in 3/12 patients, two of whom presented a complete response to gemcitabine. These data provide evidence that the chemotherapeutic activity of the combination of gemcitabine and pemetrexed is synergistic against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.

KW - Antifolates

KW - Bladder cancer

KW - Drug combination

KW - Gemcitabine

KW - Inducible gene expression

UR - http://www.scopus.com/inward/record.url?scp=33746915066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746915066&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6603242

DO - 10.1038/sj.bjc.6603242

M3 - Article

C2 - 16868547

AN - SCOPUS:33746915066

VL - 95

SP - 289

EP - 297

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -